NWT

NWT (Natural Wellness Technologies) is a clinical-stage biotechnology company based in the Netherlands that specializes in the discovery and development of bioactive peptides for metabolic and cardiovascular health. The company utilizes a proprietary platform to identify functional peptides from natural sources, such as egg and soy, which are then optimized for therapeutic use. NWT's lead candidate, NWT-03, is an egg-white derived peptide targeting hypertension through ACE inhibition and has demonstrated efficacy in Phase 2 clinical trials. The company's broader pipeline addresses significant unmet needs in muscle health (sarcopenia) and glucose metabolism, positioning NWT as a leader in peptide-based solutions for the aging population.